Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 3 - The Real Truth

Weight-loss race: how switch from injections to pills is expanding big pharma’s hopes

Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade

The Guardian - UK

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

MarketBeat

AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca profits jump by 40% amid strong demand for cancer drugs

Shares edged 1% higher in morning trading on Tuesday, with the stock having risen 28% in the past six months.

Evening Standard

GSK, take two: the bullish tone at the top is finally more convincing

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential

The Guardian - UK

FTSE 100 sets new record despite metals meltdown

Gold was quoted lower at 4,696.11 dollars an ounce on Monday, down sharply against 5,003.82 dollars at the same time on Friday.

Evening Standard

AstraZeneca shares launch on New York Stock Exchange

The UK based-pharmaceutical giant is transitioning to the market by delisting American Depositary Shares from the Nasdaq index.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca secures tie-up with Chinese firm for weight loss drugs

The deal includes giving AstraZeneca access to the exclusive global rights, outside China, to CSPC’s once-a-month weight management jabs.

Evening Standard

FTSE 100 Live 30 January: Gold and silver prices slump, AstraZeneca strikes China deal

The price of gold today fell back as traders focused on President Trump’s nomination as next Federal Reserve chair.

Evening Standard

AstraZeneca to invest £11bn in China after rowing back on UK expansion

Keir Starmer says the move, announced during his trip to Beijing, will help support thousands of British jobs

The Guardian - UK

Who is on Keir Starmer's China trip, and why are they there?

A delegation of ministers, business leaders and cultural figures are part of the trip, as the Prime Minister seeks to improve relations

Evening Standard

From wildfires to inhalers: The hidden environmental cost of respiratory care and how tech may help

As climate change worsens respiratory diseases, doctors and drugmakers are exploring earlier diagnosis and low-carbon inhalers to cut emissions from care and protect patients.

Euronews

FTSE 100 hits new record high as New Year rally gains momentum

The blue-chip index rose to new heights after a strong day of trading for drugmakers and some of the UK’s biggest retailers.

Evening Standard

Next impresses as FTSE 100 rockets to fresh high

Next, up 5%, impressed the City with strong Christmas sales.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Revealed: how big businesses are rolling back public support for Pride

Guardian analysis of 20 major companies in UK and US shows mentions of Pride on social media have fallen substantially in past two years

The Guardian - UK

US is the best place for drug companies to invest, says boss of London-based GSK

Emma Walmsley’s praise for US pharmaceutical market piles pressure on UK government

The Guardian - UK

What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives

More than £3bn that could have been used for UK patients will go to big pharma for its branded products, says Guardian columnist Aditya Chakrabortty

Benzinga

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks

U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership team to initiate new safety inquiries.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca's Hard To Control Hypertension Drug Advances, With FDA Decision Expected In 2026

On Tuesday, the U.S. Food and Drug Administration accepted AstraZeneca Plc's (NASDAQ:AZN) New Drug Application (NDA) for baxdrostat for adult patients with hard-to-control (uncontrolled or treatment-resistant) hypertension as an add-on to other antihypertensive medicines.

Euronews

UK and US agree on zero-tariff pharma deal after months of tensions

London and Washington have found a compromise that would avoid US tariffs on British medicines — but only after the UK agreed to pay more for cutting-edge drugs.

Benzinga

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers

The U.S. Food and Drug Administration (FDA) on Tuesday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Benzinga

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ:AZN), initially established in March 2025.

Benzinga

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

Benzinga

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.

The Guardian - UK

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.